CBIH Achieves $2 Billion Valuation Following StoneBridge Advisory Assessment
Houston, Texas–(Newsfile Corp. – June 17, 2024) – Cannabis Bioscience International Holdings (OTC PINK: CBIH) has been valued at $2 Billion following a rigorous evaluation by StoneBridge Advisory, a leading financial advisory firm based in Los Angeles, California.
StoneBridge’s assessment highlights CBIH’s formidable market presence, cutting-edge product offerings, and solid business framework. Moreover, this valuation serves as a testament to investor and analyst optimism regarding CBIH’s capacity for sustained growth and expansion.
The valuation was reached through a comprehensive review of CBIH’s financial metrics, market penetration, industry competition, and strategic planning. Additionally, it took into account the exceptional skill sets within the company. Including securities attorney; corporate attorney, patent attorney, in-house counsel, comptroller with a Magister Scientiarum in Administration, CPA, PCAOB, graphic designer, Master’s Degree in Audiovisual Communication and Advertising Content, Ph.D.-level scientists with emphasis on microbiology, medical professionals certified in cancer biology, peritoneal dialysis, pregnancy-related emergency care, as well as board-certified in General medicine and internal medicine, Anti-aging medicine Specialist, Master of Health Care Administration, and Doctorate in Dental Surgery. These experts have contributed to the development of a diversified portfolio of innovative therapies and medical solutions over the past 15 years. Their work addresses gaps in conventional treatments, and provides natural alternatives for widespread health issues globally.
StoneBridge Advisory employed meticulous due diligence and sophisticated financial modeling during the valuation process to guarantee precision and accurately represent the value of CBIH.
John Jones, Treasurer and Director of CBIH, commented on the significance of this valuation, stating: “We have been meticulously reconstructing our company and reinforcing its foundations. Given the promising opportunities we’ve identified, obtaining a valuation became the next logical step to gauge our progress and plan for future growth.” He further noted, “Being positioned in rapidly evolving sectors like medical cannabis, clinical research, and biotechnology, coupled with our unparalleled expertise, positions us uniquely to seize advantageous opportunities that will benefit both our company and shareholders.”
This landmark $2 Billion valuation positions CBIH among an elite group of startups and fresher/emerging companies that have achieved such a notable feat. This milestone paves the way for CBIH to pursue strategic alliances, investment opportunities, and ambitious expansion strategies, further cementing its status as a leader in the cannabis bioscience sector.
FORWARD-LOOKING STATEMENTS
This press release may contain forward-looking statements. The words “believe,” “expect,” “should,” “intend,” “estimate,” “projects,” variations of such words and similar expressions identify forward-looking statements, but their absence does not mean that a statement is not a forward-looking statement. These forward-looking statements are based upon the Company’s current expectations and are subject to a number of risks, uncertainties, and assumptions. The Company undertakes no obligation to update any forward-looking statements, whether as a result of new information, future events, or otherwise. Among the important factors that could cause actual results to differ significantly from those expressed or implied by such forward-looking statements are risks that are detailed in the Company’s filings, which are on file at www.OTCmarkets.com.
For more information contact us at:
(214) 733-0868
ir@cbih.net
Dante Picazo
CEO – CBIH
Website: www.cbih.net
X: www.twitter.com/cbihstock
Instagram: www.instagram.com/CBIHSTOCK
Investor Relations:
East Coast
Peter Nicosia
Bull in Advantage, LLC
Phone: 585-703-6565
Email: Info@BlueHorseshoeStocks.com
West Coast
Zach Logan
Pacific Capital Markets LLC
Phone: 858.864.0011
Email: pacificcapitalmarketsllc@gmail.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/213088
